利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.023 秒)

    Sustained release delivery of isradipine
    1.
    发明申请
    Sustained release delivery of isradipine 审中-公开
    持续释放异癸嗪

    公开(公告)号：US20060210623A1

    公开(公告)日：2006-09-21

    申请号：US11377648

    申请日：2006-03-17

    申请人： Paul Stach ,  Balaji Kadri ,  George Bobotas ,  Abdel Fawzy

    发明人： Paul Stach ,  Balaji Kadri ,  George Bobotas ,  Abdel Fawzy

    IPC分类号： A61K9/52 ,  A61K9/22

    CPC分类号： A61K9/2027

    摘要： Sustained release oral formulations of israpidine, methods of preparing same, and methods of using sustained release oral formulations to provide controlled delivery of israpidine. The sustained release oral formulations include israpidine and a sustained release polymer, and provide substantially zero order release of israpidine over an extended period.

    摘要翻译： 缓释口服制剂的异。啶，其制备方法，以及使用缓释口服制剂提供受控制的异 持续释放的口服制剂包括异哌啶和持续释放聚合物，并且在延长的时间内提供基本上零次释放的阿片苷。

    Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution
    4.
    发明申请
    Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution 审中-公开
    用尼扎替丁口服溶液治疗胃肠道疾病的组成，系统和方法

    公开(公告)号：US20060094760A1

    公开(公告)日：2006-05-04

    申请号：US11048051

    申请日：2005-02-02

    申请人： Abdel Fawzy ,  George Bobotas ,  Keith Rotenberg

    发明人： Abdel Fawzy ,  George Bobotas ,  Keith Rotenberg

    IPC分类号： A61K31/445

    CPC分类号： A61K31/445

    摘要： An alcohol-free, oral solution of nizatidine treats gastric and intestinal disorders. Oral doses of solution, which are equivalent to 150 mg twice daily, or 300 mg once daily, pill form of conventional nizatidine are orally administered and have a bioequivalency greater than 70%. The oral solution allows a wider population to obtain nizatidine treatment, particularly children, and the elderly, who have difficulty ingesting pills, can take the oral solution. Also, adolescents and younger children, in particular, can be treated with an alcohol-free oral solution.

    摘要翻译： 不含酒精的尼日替他口服溶液治疗胃肠道疾病。 经口施用口服剂量的溶液，相当于每日两次，每日两次，或300mg，每日一次，常规尼扎替丁的药丸形式，其生物等效性大于70％。 口服溶液使更广泛的人群能够获得尼日利亚治疗，特别是儿童，而且难以摄入丸剂的老年人可以服用口服溶液。 此外，特别是青少年和年龄较小的儿童可以用无酒精的口服液治疗。

    Time-sustained-release formulations comprising a beta-blocker
    5.
    发明申请
    Time-sustained-release formulations comprising a beta-blocker 审中-公开
    包含β-阻滞剂的时间缓释制剂

    公开(公告)号：US20080131517A1

    公开(公告)日：2008-06-05

    申请号：US11896616

    申请日：2007-09-04

    申请人： Abdel Fawzy ,  George Bobotas

    发明人： Abdel Fawzy ,  George Bobotas

    IPC分类号： A61K9/14 ,  A61K31/138

    CPC分类号： A61K9/5084 ,  A61K31/138

    摘要： The present invention relates to compositions and methods of treating human subjects with a beta-adrenergic receptor blocking agent (“beta-blocker”) provided in a time-sustained-release delivery system. The time-sustained-release drug delivery systems includes at least three populations of beads, where each population of beads includes a beta-blocker. The beads may be selected from immediate-release beads, enteric-release beads, sustained-release beads, and time-sustained-release beads. The beta-blocker may be selected from acebutolol, atenolol, betaxolol, bisoprolol, esmolol, metoprolol, nebivolol, butoxamine, carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, propranolol, pindolol, sotalol, and timolol. According to presently preferred embodiments, the beta-blocker is propranolol. The dosage forms of the present invention are useful for treating conditions including hypertension, angina pectoris due to coronary atherosclerosis, hypertrophic subaortic stenosis, congestive heart failure, arrhythmias, angina, anxiety, glaucoma, migraines, esophageal varices, alcohol withdrawal syndrome, irregular heartbeat, tachycardia, tremor, and neuroleptic-induced akathisia. They are also useful in the prophylaxis of migraine headaches.

    摘要翻译： 本发明涉及在时间 - 缓释递送系统中提供的β-肾上腺素能受体阻断剂（“β-阻滞剂”）治疗人受试者的组合物和方法。 时间缓释药物递送系统包括至少三个珠粒，其中每个珠粒含有β-阻滞剂。 珠子可以选自立即释放珠粒，肠释放珠粒，缓释珠粒和时间缓释珠粒。 β-阻断剂可以选自乙酰托洛尔，阿替洛尔，倍他洛尔，比索洛尔，艾司洛尔，美托洛尔，奈比洛尔，丁胺，卡替洛尔，卡维地洛，拉贝洛尔，纳多洛尔，奥普洛尔，依布洛尔，普萘洛尔，吲哚洛尔，索他洛尔和噻吗洛尔。 根据目前优选的实施方案，β-阻断剂是普萘洛尔。 本发明的剂型可用于治疗冠状动脉粥样硬化引起的高血压，心绞痛，肥厚性主动脉瓣狭窄，充血性心力衰竭，心律失常，心绞痛，焦虑，青光眼，偏头痛，食管静脉曲张，酒精戒断综合征，不规则心跳， 心动过速，震颤和精神安定药诱导的睡眠障碍。 它们也可用于预防偏头痛。

    Coating capsules with active pharmaceutical ingredients
    7.
    发明申请
    Coating capsules with active pharmaceutical ingredients 有权
    涂层胶囊与活性药物成分

    公开(公告)号：US20070212411A1

    公开(公告)日：2007-09-13

    申请号：US11716020

    申请日：2007-03-09

    申请人： Abdel Fawzy ,  George Bobotas

    发明人： Abdel Fawzy ,  George Bobotas

    IPC分类号： A61K9/52 ,  A61K9/48

    CPC分类号： A61K9/4891 ,  A61K9/4808

    摘要： Pharmaceutical compositions in unit dose form comprising capsules containing one or more first active pharmaceutical ingredient in a pharmaceutically acceptable vehicle, coated with one or more second active pharmaceutical ingredients, wherein the unit dose form is a pharmaceutical grade finished dosage form, and methods of making and using the same.

    摘要翻译： 单位剂量形式的药物组合物，其包含在药学上可接受的载体中含有一种或多种第一活性药物成分的胶囊，其涂覆有一种或多种第二活性药物成分，其中所述单位剂量形式是药物级成品剂型，以及制备和 使用相同

    Coating capsules with active pharmaceutical ingredients
    9.
    发明授权
    Coating capsules with active pharmaceutical ingredients 有权
    涂层胶囊与活性药物成分

    公开(公告)号：US08784886B2

    公开(公告)日：2014-07-22

    申请号：US11716020

    申请日：2007-03-09

    申请人： Abdel Fawzy ,  George Bobotas

    发明人： Abdel Fawzy ,  George Bobotas

    IPC分类号： A61K9/48 ,  A61K9/64 ,  A61K9/52

    CPC分类号： A61K9/4891 ,  A61K9/4808

    摘要： Pharmaceutical compositions in unit dose form comprising capsules containing one or more first active pharmaceutical ingredient in a pharmaceutically acceptable vehicle, coated with one or more second active pharmaceutical ingredients, wherein the unit dose form is a pharmaceutical grade finished dosage form, and methods of making and using the same.

    摘要翻译： 单位剂量形式的药物组合物，其包含在药学上可接受的载体中含有一种或多种第一活性药物成分的胶囊，其涂覆有一种或多种第二活性药物成分，其中所述单位剂量形式是药物级成品剂型，以及制备和 使用相同